Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2005

01-01-2005 | Article

The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study

Authors: T. Costacou, J. C. Zgibor, R. W. Evans, J. Otvos, M. F. Lopes-Virella, R. P. Tracy, T. J. Orchard

Published in: Diabetologia | Issue 1/2005

Login to get access

Abstract

Aims/hypothesis

Recent findings suggest the potential involvement of adiponectin in obesity, diabetes and cardiovascular disease. We assessed the prospective association between adiponectin concentration and coronary artery disease in individuals with type 1 diabetes.

Methods

Participants were identified from the Pittsburgh Epidemiology of Diabetes Complications cohort, a prospective follow-up study of childhood-onset type 1 diabetes. At baseline, subjects had a mean age of 28 years, and a mean diabetes duration of 19 years. Cases (determined by physician-diagnosed angina, confirmed myocardial infraction, stenosis ≥50%, ischemic ECG or revascularization) were matched to the control subjects with respect to sex, age and diabetes duration. Samples and risk factors for analyses were identified from the earliest exam prior to incidence in cases. Sera and information on all covariates were available for 28 cases and 34 control subjects. Proportional hazards models were constructed including matching variables.

Results

Compared with those in men, adiponectin concentrations were elevated in females (p=0.009) and among individuals with macroalbuminuria (p=0.04). In multivariable analyses (adjusting for standard risk factors as well as lipoprotein measurements determined by nuclear magnetic resonance spectroscopy, E-selectin or antioxidants), adiponectin inversely predicted the incidence of coronary artery disease (hazard ratio=0.37 per 1 SD increase, 95% CI 0.19–0.73, p=0.004).

Conclusions/interpretation

The results suggest that increased adiponectin concentration is prospectively associated with a lower risk of coronary artery disease type 1 diabetes. The potential of adiponectin determination as a useful marker of, and potential therapeutic target for, coronary artery disease prevention in type 1 diabetes should be further explored.
Literature
1.
Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286–289CrossRefPubMed
2.
Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83CrossRefPubMed
3.
Okamoto Y, Arita Y, Nishida M et al (2000) An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32:47–50PubMed
4.
Ouchi N, Kihara S, Arita Y et al (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein, adiponectin. Circulation 100:2473–2476PubMed
5.
Yokota, T, Oritani K, Takahashi I et al (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723–1732PubMed
6.
Takahashi M, Arita Y, Yamagata K et al (2000) Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 24:861–868
7.
Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946CrossRefPubMed
8.
Kubota N, Terauchi Y, Yamauchi T et al (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863–25866CrossRefPubMed
9.
Matsuda M, Shimomura I, Sata M et al (2002) Role of adiponectin in preventing vascular stenosis. J Biol Chem 277:37487–37491CrossRefPubMed
10.
Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935CrossRefPubMed
11.
Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599PubMed
12.
Zoccali C, Mallamaci F, Tripepi G et al (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–141
13.
Orchard TJ, Olson JC, Erbey JR et al (2003) Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 26:1374–1379PubMed
14.
Hara K, Boutin P, Mori Y et al (2002) Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536–540PubMed
15.
Kondo H, Shimomura I, Matsukawa Y et al (2002) Association of adiponectin mutation with type 2 diabetes. A candidate gene for the insulin resistance syndrome. Diabetes 51:2325–2328PubMed
16.
Stumvoll M, Tschritter O, Frutschhe A et al (2002) Association of the T-G polymorphism in adiponectin (Exon 2) with obesity and insulin sensitivity. Diabetes 51:37–41PubMed
17.
Orchard TJ, Dorman JS, Maser RE et al (1990) Prevalence of complications of IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39:741–747
18.
Orchard TJ, Dorman JS, Maser RE et al (1990) Factors associated with avoidance of severe complications after 25 yr of IDDM: Pittsburgh Epidemiology of Diabetes Complications Study—I. Diabetes Care 13:741–747
19.
Wagener DK, Sacks JM, LaPorte RE, MacGregor JM (1982) The Pittsburgh study of insulin-dependent diabetes mellitus: risk for diabetes among relatives of IDDM. Diabetes 31:136–144PubMed
20.
Borhani NO, Kass EH, Langford HG, Payne GH, Remington RD, Stamler J (1976) The hypertension detection and follow-up program. Prev Med 5:207–215CrossRefPubMed
21.
Beck AT, Steer RA, Garbin MG (1988) Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 8:77–100CrossRef
22.
Warnick GR, Albers JJ (1978) Heparin-Mn2+ quantitation of high-density-lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 24:900–904PubMed
23.
National Institutes of Health, Department of Health (1975) Lipid research clinics program. US Government Printing Office, Washington, D.C., pp 75–628
24.
Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20:470–475PubMed
25.
Bucolo G, David H (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19:476–482PubMed
26.
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
27.
Williams KV, Erbey JR, Becker DJ, Arslanian S, Orchard TJ (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626–632PubMed
28.
Macy E, Hayes T, Tracy R (1997) Variability in the measurement of C-reactive protein in health subjects: implication for reference interval and epidemiological applications. Clin Chem 43:52–58PubMed
29.
Driskell WJ, Neese JW, Bryant CC, Bashor MM (1982) Measure of vitamin A and vitamin E in human serum by high performance liquid chromatography. J Chromatogr 231:439–444CrossRef
30.
Miller KW, Lorr NA, Yang CS (1984) Simultaneous determination of plasma retinol, α-tocopherol, lycopene, α-carotene and β-carotene by high-performance liquid chromatography. Anal Biochem 138:340–345CrossRefPubMed
31.
Otvos JD (2002) Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48:171–180PubMed
32.
Ellis D, Buffone GJ (1977) A new approach to the evaluation of proteinuric states. Clin Chem 23:666–670PubMed
33.
Ellis D, Coonrod BA, Dorman JS et al (1989) Choice of urine sample predictive of microalbuminuria in patients with insulin-dependent diabetes mellitus. Am J Kidney Dis 4:321–328
34.
Assadi FK, John EG, Fornell L, Rosenthal IM (1985) Falsely elevated serum creatinine concentration in ketoacidosis. J Pediatr 107:562–564
35.
Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ (2003) Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 46:674–682CrossRefPubMed
36.
Costacou T, Zgibor JC, Walsh M, Lopes-Virella MF, Otvos J, Orchard TJ (2003) Why is E-selectin such a good predictor of coronary artery disease in type 1 diabetes? The Pittsburgh Epidemiology of Diabetes Complications Study. Circulation 108:3370 (Abstract)
37.
Costacou T, Evans RW, Tyurina YY, Kagan VE, Orchard TJ (2004) Antioxidants and coronary artery disease among individuals with type 1 diabetes: findings from the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. In: Proceedings of the 39th annual meeting of the European Diabetes Epidemiology Group (EDEG): 44 (Abstract)
38.
Yang WS, Lee WJ, Funahashi T et al (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815–3819
39.
Stefan N, Vozarova B, Funahashi T et al (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51:1884–1888PubMed
40.
Spranger J, Kroke A, Mohlig M et al (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228CrossRefPubMed
41.
Imagawa A, Funahashi T, Nakamura T et al (2002) Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 25:1665–1666PubMed
42.
Perseghin G, Lattuada G, Danna M et al (2003) Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 285:E1174–E1181
43.
Cnop M, Havel PJ, Utzschneider KM et al (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459–469PubMed
44.
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HE (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749CrossRefPubMed
45.
Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2002) Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290:1084–1089
46.
Yu JG, Javorschi S, Hevener AL et al (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–2974PubMed
47.
Nishizawa H, Shimomura I, Kishida K et al (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741PubMed
48.
Looker H, Funahashi T, Krakoff J et al (2003) Relationship between serum adiponectin levels and measures of renal function in type 2 diabetes. Diabetes 52 [Suppl 1]:41A (Abstract)
49.
Diez JJ, Iglesias P (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148:293–300PubMed
50.
Koshimura J, Fujita H, Narita T, Shimotomai T et al (2004) Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun 316:165–169
51.
Emoto M, Kanda H, Shoji T et al (2001) Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 24:533–538PubMed
Metadata
Title
The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study
Authors
T. Costacou
J. C. Zgibor
R. W. Evans
J. Otvos
M. F. Lopes-Virella
R. P. Tracy
T. J. Orchard
Publication date
01-01-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1597-y

Other articles of this Issue 1/2005

Diabetologia 1/2005 Go to the issue

Article

Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus

Article

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes

Editorial

Your journal and mine

Article

Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets

Article

Leisure time physical activity and the risk of type 2 diabetes in men and women from the general population

Article

Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits